Glucagon-like peptide-1 receptor agonists as a Therapeutic Option for Antipsychotic-Induced Obesity: A Review of Current Evidence
Introduction Obesity affects over 650 million adults worldwide and is a major risk factor for cardiovascular diseases and type 2 diabetes. Among those affected are patients treated with antipsychotics, such as clozapine and olanzapine, which often lead to significant weight gain, increasing the ris...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Kazimierz Wielki University
2024-12-01
|
| Series: | Journal of Education, Health and Sport |
| Subjects: | |
| Online Access: | https://apcz.umk.pl/JEHS/article/view/56672 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850168196518117376 |
|---|---|
| author | Natalia Gniaź Aleksandra Górska Wiktor Grela Jagoda Niewiadomska Daria Furtak Dawid Tulej Paulina Głogowska Alicja Dziedzic Dominika Marciniuk Natalia Marko |
| author_facet | Natalia Gniaź Aleksandra Górska Wiktor Grela Jagoda Niewiadomska Daria Furtak Dawid Tulej Paulina Głogowska Alicja Dziedzic Dominika Marciniuk Natalia Marko |
| author_sort | Natalia Gniaź |
| collection | DOAJ |
| description |
Introduction
Obesity affects over 650 million adults worldwide and is a major risk factor for cardiovascular diseases and type 2 diabetes. Among those affected are patients treated with antipsychotics, such as clozapine and olanzapine, which often lead to significant weight gain, increasing the risk of metabolic syndrome. Recent advances with glucagon-like peptide-1 receptor agonists (GLP-1 RAs), including semaglutide and liraglutide, show promise in addressing antipsychotic-induced obesity by reducing weight and improving metabolic health.
Purpose
The aim of this review is to present an overview of the current state of knowledge regarding the efficacy of GLP-1 RAs in the treatment of antipsychotic-induced obesity.
Materials and methods
This review is based on both original research studies and review articles identified through a comprehensive search of the PubMed database, using the following search terms: obesity, antipsychotic-induced weight gain, clozapine, olanzapine, adverse effect, GLP-1 receptors agonist.
Description of the state of knowledge
GLP-1 RAs significantly reduce body weight and adipose tissue by suppressing appetite, particularly for high-fat foods. Clinical trials show improvements in lipid profiles, blood pressure, and inflammation, contributing to better metabolic health. However, their long-term effects, especially with different antipsychotics, remain insufficiently studied.
Conclusions
GLP-1 RAs show significant potential for managing antipsychotic-induced obesity, but further research is needed to assess long-term efficacy and safety in this population.
|
| format | Article |
| id | doaj-art-3bf329c97d1d4b449defda012340a3de |
| institution | OA Journals |
| issn | 2391-8306 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Kazimierz Wielki University |
| record_format | Article |
| series | Journal of Education, Health and Sport |
| spelling | doaj-art-3bf329c97d1d4b449defda012340a3de2025-08-20T02:21:02ZengKazimierz Wielki UniversityJournal of Education, Health and Sport2391-83062024-12-017510.12775/JEHS.2024.75.56672Glucagon-like peptide-1 receptor agonists as a Therapeutic Option for Antipsychotic-Induced Obesity: A Review of Current EvidenceNatalia Gniaź0Aleksandra Górska1Wiktor Grela2Jagoda Niewiadomska3Daria Furtak4Dawid Tulej5Paulina Głogowska6Alicja Dziedzic7Dominika Marciniuk8Natalia MarkoUniwersytet Medyczny w LublinieUniwersytet Medyczny w LublinieUniwersytet Medyczny w LublinieUniwersytet Medyczny w LublinieUniwersytet Medyczny w LublinieUniwersytet Medyczny w LublinieUniwersytet Medyczny w LublinieUniwersytet Medyczny w LublinieUniwersytet Medyczny w Lublinie Introduction Obesity affects over 650 million adults worldwide and is a major risk factor for cardiovascular diseases and type 2 diabetes. Among those affected are patients treated with antipsychotics, such as clozapine and olanzapine, which often lead to significant weight gain, increasing the risk of metabolic syndrome. Recent advances with glucagon-like peptide-1 receptor agonists (GLP-1 RAs), including semaglutide and liraglutide, show promise in addressing antipsychotic-induced obesity by reducing weight and improving metabolic health. Purpose The aim of this review is to present an overview of the current state of knowledge regarding the efficacy of GLP-1 RAs in the treatment of antipsychotic-induced obesity. Materials and methods This review is based on both original research studies and review articles identified through a comprehensive search of the PubMed database, using the following search terms: obesity, antipsychotic-induced weight gain, clozapine, olanzapine, adverse effect, GLP-1 receptors agonist. Description of the state of knowledge GLP-1 RAs significantly reduce body weight and adipose tissue by suppressing appetite, particularly for high-fat foods. Clinical trials show improvements in lipid profiles, blood pressure, and inflammation, contributing to better metabolic health. However, their long-term effects, especially with different antipsychotics, remain insufficiently studied. Conclusions GLP-1 RAs show significant potential for managing antipsychotic-induced obesity, but further research is needed to assess long-term efficacy and safety in this population. https://apcz.umk.pl/JEHS/article/view/56672obesityantipsychotic-induced weight gainclozapineolanzapineadverse effectGLP-1 receptors agonist |
| spellingShingle | Natalia Gniaź Aleksandra Górska Wiktor Grela Jagoda Niewiadomska Daria Furtak Dawid Tulej Paulina Głogowska Alicja Dziedzic Dominika Marciniuk Natalia Marko Glucagon-like peptide-1 receptor agonists as a Therapeutic Option for Antipsychotic-Induced Obesity: A Review of Current Evidence Journal of Education, Health and Sport obesity antipsychotic-induced weight gain clozapine olanzapine adverse effect GLP-1 receptors agonist |
| title | Glucagon-like peptide-1 receptor agonists as a Therapeutic Option for Antipsychotic-Induced Obesity: A Review of Current Evidence |
| title_full | Glucagon-like peptide-1 receptor agonists as a Therapeutic Option for Antipsychotic-Induced Obesity: A Review of Current Evidence |
| title_fullStr | Glucagon-like peptide-1 receptor agonists as a Therapeutic Option for Antipsychotic-Induced Obesity: A Review of Current Evidence |
| title_full_unstemmed | Glucagon-like peptide-1 receptor agonists as a Therapeutic Option for Antipsychotic-Induced Obesity: A Review of Current Evidence |
| title_short | Glucagon-like peptide-1 receptor agonists as a Therapeutic Option for Antipsychotic-Induced Obesity: A Review of Current Evidence |
| title_sort | glucagon like peptide 1 receptor agonists as a therapeutic option for antipsychotic induced obesity a review of current evidence |
| topic | obesity antipsychotic-induced weight gain clozapine olanzapine adverse effect GLP-1 receptors agonist |
| url | https://apcz.umk.pl/JEHS/article/view/56672 |
| work_keys_str_mv | AT nataliagniaz glucagonlikepeptide1receptoragonistsasatherapeuticoptionforantipsychoticinducedobesityareviewofcurrentevidence AT aleksandragorska glucagonlikepeptide1receptoragonistsasatherapeuticoptionforantipsychoticinducedobesityareviewofcurrentevidence AT wiktorgrela glucagonlikepeptide1receptoragonistsasatherapeuticoptionforantipsychoticinducedobesityareviewofcurrentevidence AT jagodaniewiadomska glucagonlikepeptide1receptoragonistsasatherapeuticoptionforantipsychoticinducedobesityareviewofcurrentevidence AT dariafurtak glucagonlikepeptide1receptoragonistsasatherapeuticoptionforantipsychoticinducedobesityareviewofcurrentevidence AT dawidtulej glucagonlikepeptide1receptoragonistsasatherapeuticoptionforantipsychoticinducedobesityareviewofcurrentevidence AT paulinagłogowska glucagonlikepeptide1receptoragonistsasatherapeuticoptionforantipsychoticinducedobesityareviewofcurrentevidence AT alicjadziedzic glucagonlikepeptide1receptoragonistsasatherapeuticoptionforantipsychoticinducedobesityareviewofcurrentevidence AT dominikamarciniuk glucagonlikepeptide1receptoragonistsasatherapeuticoptionforantipsychoticinducedobesityareviewofcurrentevidence AT nataliamarko glucagonlikepeptide1receptoragonistsasatherapeuticoptionforantipsychoticinducedobesityareviewofcurrentevidence |